15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 7 firms covering Exagen Inc, 7 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $8.00 to $12.00, a moderate spread. The average target of $9.57 sits 31% above the current $7.31. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.16 next quarter toward $-0.44 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 ratings
Strong Buy
Strong Buy00%
Buy7100%
Hold00%
Sell00%
Strong Sell00%
Based on 7 analysts giving stock ratings to Exagen Inc.
As of Sep, 7 of 7 firms rate XGN a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
XGN EPS & revenue forecast
EPS · NEXT QUARTER
$-0.16
Range $-0.16 – $-0.16 · 2 analysts · -40% YoY
Next period, 2 analysts expect Exagen Inc to earn $-0.16 a share (range $-0.16 – $-0.16), versus $-0.27 a year earlier. Full-year consensus is $-0.62, growing to $-0.44 the year after.
REVENUE · NEXT QUARTER
$18.3M
Range $18.1M – $18.8M · 2 analysts · +10% YoY
Revenue is expected to reach $18.3M (range $18.1M – $18.8M), +10.2% year-over-year. Full-year consensus is $73.9M, rising to $81.4M next year.
Top analysts covering Exagen Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on XGN.
#1
Ross Osborn
Cantor Fitzgerald · Rank #166
Buy
$10.00+36.8% to target
Overall win rate
33%
+ Follow
#2
KM
Kyle Mikson
Canaccord Genuity · Rank #263
Buy
$8.00+9.4% to target
Overall win rate
34%
+ Follow
#3
Paul Knight
Keybanc · Rank #341
Buy
$10.00+36.8% to target
Overall win rate
35%
+ Follow
#4
Mark Massaro
BTIG
Buy
$9.00+23.1% to target
Coverage
—
+ Follow
#5
AS
Anderson Schock
B. Riley Securities
Buy
$12.00+64.2% to target
Coverage
—
+ Follow
XGN stock forecast FAQ
What is XGN's average 12-month price target?+
The 7 analysts with a live target average $9.57 for Exagen Inc over the next 12 months, ranging from a $12.00 high to a $8.00 low.
Is XGN stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 7 analyst ratings, 7 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for XGN?+
The Street-high target is $12.00 (B. Riley Securities), and the Street-low is $8.00 (Roth Capital). The average of all 7 active targets is $9.57.
How many Wall Street analysts cover XGN?+
7 analysts have an active rating on Exagen Inc, and 7 firms carry a live 12-month price target.
Who is the most accurate analyst covering XGN?+
Among analysts who currently cover XGN, Ross Osborn of Cantor Fitzgerald has the strongest overall Quantellect track record (Rank #166). Their current call is Buy with a $10.00 target.
What is Exagen Inc's projected EPS for next quarter?+
The consensus estimate is $-0.16 per share (range $-0.16 – $-0.16) across 2 analysts. Full-year EPS is projected at $-0.62, rising to $-0.44 the following year.
How much revenue is Exagen Inc expected to report next quarter?+
Consensus revenue is $18.3M (range $18.1M – $18.8M). Full-year revenue is projected at $73.9M, growing to $81.4M next year.
Have analysts been upgrading or downgrading XGN lately?+
As of Sep, 7 of 7 firms rate XGN a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their XGN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
